Tesamorelin
Also known as: Egrifta
Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.
Who's worth your money for Tesamorelin
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 40 scored sellers
$67.99 · 20mg · 99.0% purity
Best value after code
$1.85/mg effective with 15% code
$43.45 · 20mg · 99.1% purity
Most tested
28 independent COAs on file
$122 · 10mg · 99.8% purity
Average price
$8.08/mg
Sellers
78
45-day trend
-17.7%
62 of 78 sellers have a current price· 4 stale hidden· 18 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 1h ago
$3.40/mg -57.9% vs avg$67.99
20mg
- 🇺🇸 Peptide Partners99
✓ verified at source · 3d ago
$12.20/mg +51% vs avg$122
10mg
- 🇺🇸 Hydro Research Peptides97
✓ verified at source · just now
$5.50/mg -31.9% vs avg$55.00
10mg
- 🇺🇸 Prime Peptides96
✓ verified at source · just now
$8.00/mg -1% vs avg$80.00
10mg
- 🇺🇸 BioLongevity Labs96
✓ verified at source · just now
$14.38/mg +78% vs avg$115
8mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · 5d ago · stale
$3.20/mg -60.4% vs avg$96.00
30mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 5d ago · stale
$8.00/mg -1% vs avg$79.99
10mg
- 🇺🇸 Profound Aminos95
✓ verified at source · 3d ago · stale
$11.00/mg +36.2% vs avg$55.00
5mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · just now
$13.10/mg +62.2% vs avg$131
10mg
- 🇺🇸 Sunrise Bioresearch95
✓ verified at source · just now
$40.00/mg +395.2% vs avg$200
5mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Tesamorelin
Get one email when the market actually moves — no newsletter, no noise.
About Tesamorelin
CAS
218949-48-5
Molecular formula
C221H366N72O67S
Sequence
YADAIFTNSY RKVLGQLSAR KLLQDIMSR QQGESNQERG ARARL
Typical dose range
2 mg/day subcutaneous (approved EGRIFTA); 1.4 mg/day (EGRIFTA SV); research use mirrors clinical dosing of 1–2 mg/day SC
Half-life
~26–38 minutes (Wikipedia / literature); FDA label reports ~8 minutes (single SC dose, healthy subjects)
COAs for Tesamorelin
345 third-party tests across 54 vendors. Each card links to the full report.
For
Tesamorelin
by VeratisBio· batch TESA0001
For
Tesamorelin
by Novaglo Research· batch 5003091526TM
For
Tesamorelin
by Peptide Plugs· batch 29310L-DK
For
Tesamorelin
by NG Peptide· batch TSM20-06
For
Tesamorelin
by Virtus Peptides· batch ZQ-20260809-TSM10-GREEN
For
Tesamorelin
by Glacier Aminos· batch TES10GA-08
For
Tesamorelin
by Sunrise Bioresearch· batch A36JHMQ
For
Tesamorelin
by Novaglo Research· batch 5003082126TM
For
Tesamorelin
by Frontier Aminos· batch TSM-14
For
Tesamorelin
by NovaForge Labs· batch NFL-0002
For
Tesamorelin
by Velora Biolabs· batch VBL-TSM10-1
For
Tesamorelin
by Velora Biolabs· batch VBL-TSM20-1
For
Tesamorelin
by Longeva· batch PM-260719-TESAMORELIN-01
For
Tesamorelin
by NovaForge Labs· batch TSM-QSCT1
For
Tesamorelin
by VoriLabs· batch TES-2607-A
For
Tesamorelin
by jdbioworks· batch 2026-002
For
Tesamorelin
by Virtus Peptides· batch NS-20260601 | TSM10-WHITE
For
Tesamorelin
by NovaForge Labs· batch Lot - 2026 - 1
For
Tesamorelin
by Artisan Aminos· batch AA-TSM10-049
For
Tesamorelin
by Peptide Plugs· batch 160-310X-DK
For
Tesamorelin
by VoriLabs· batch TES-2606-A
For
Tesamorelin
by NG Peptide· batch TSM-13
For
Tesamorelin
by Optima Supply· batch OS-2026-1763
For
Tesamorelin
by Hydro Research Peptides· batch HR-2026-4509
23 citations indexed for Tesamorelin
Study · 2026
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
Background The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on physical function.
review · 2026
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review
Introduction Peptide-based therapies are increasingly used in urology and sexual medicine, although adoption is often influenced by off-label prescribing, direct-to-consumer promotion, and limited long-term safety data. We review mechanisms, clinical evidence, dosing, safety, and regulatory status of these agents.
case-report · 2026
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).
animal · 2026
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model
The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.
meta-analysis · 2026
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.
Study · 2026